3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
NIH
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Lung Neoplasms
4
Multiple Pulmonary Nodules
2
Colorectal Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Solitary Pulmonary Nodule
1
Smoking Cessation
1
Small Cell Lung Carcinoma
1
Recurrence
1
Melanoma
1
Lymphoma, Follicular
1
Lung Diseases
1
Inflammatory Bowel Diseases
1
Head and Neck Neoplasms
1
Glioma
1
Depressive Disorder, Major
1
Breast Neoplasms
1
Breast Neoplasm Female
1
Bone Neoplasms
1
Barrett Esophagus
1
Adenocarcinoma of Lung
1
Adenocarcinoma
1
Interventions
Carboplatin
49
Etoposide
46
Cisplatin
42
Topotecan
39
Irinotecan
21
Paclitaxel
20
Nivolumab
15
pembrolizumab
13
Gemcitabine
13
atezolizumab
11
Ipilimumab
11
durvalumab
9
Radiotherapy
9
Doxorubicin
7
Bevacizumab
7
rovalpituzumab tesirine
6
etoposide phosphate
6
amrubicin
6
Psychiatric Rehabilitation
6
PM 01183
6
Docetaxel
6
Counseling
6
trilaciclib
5
Temozolomide
5
Sunitinib
5
Platinum
5
Imatinib Mesylate
5
Cyclophosphamide
5
Bortezomib
5
130-nm albumin-bound paclitaxel
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Small Cell Lung Carcinoma
×
Diagnostic Imaging
×
Clear all
NCT00047385
2014-05-20
NLST
National Cancer Institute (NCI)
Phase 3
Completed
53,454 enrolled
15 charts